Australia’s Therapeutic Goods Administration (TGA) has approved a new at-home self-test kit for chlamydia and gonorrhea, specifically designed for women and individuals with a vagina. The test, developed by Sydney-based Touch Biotechnology, will be available in pharmacies starting December 13.
Key Features of the Test
The self-test kit targets two of the most common bacterial sexually transmitted infections (STIs): chlamydia and gonorrhea. The test involves collecting a vaginal swab and mixing the sample with two solutions before adding drops to a testing cassette. Results, similar to an at-home COVID-19 test, are ready in about 15 minutes, with two lines indicating a likely infection.
Who Should Use It?
The test is designed for individuals who suspect an STI, including those without symptoms, as both infections often present with none. However, symptoms like unusual discharge, pain, or bleeding may prompt earlier testing. To ensure accurate results, users are advised to wait 7–14 days after potential exposure before testing.
While the test offers convenience, a positive result requires confirmation through a laboratory test and consultation with a healthcare provider for treatment.
Accuracy and Accessibility
Touch Biotechnology claims the test has a sensitivity exceeding 99%, though these figures are not yet peer-reviewed. The test will not be subsidized under Medicare, meaning customers must pay out-of-pocket. Pricing details are not yet available.
Broader Implications for Sexual Health
This approval adds to Australia’s growing portfolio of at-home STI testing, following the introduction of self-test kits for HIV in 2021. Research on HIV self-tests shows they increase testing rates and access for underrepresented groups, such as younger individuals or those from culturally diverse backgrounds.
At-home testing for chlamydia and gonorrhea could help curb the rise of STI cases in Australia, reducing untreated infections that may lead to complications, such as fertility issues from untreated chlamydia.
Limitations and Importance of Clinical Consultation
While the at-home test enhances privacy and accessibility, it is not a substitute for comprehensive sexual health check-ups. Healthcare professionals can address broader concerns like other STIs, contraception, and vaccinations.
Those experiencing symptoms like pelvic pain or discomfort during sex should seek medical advice, as the test only detects chlamydia and gonorrhea and may miss other conditions.
As reported by medicalxpress, the introduction of this test marks a significant step forward in improving sexual health accessibility and awareness across Australia.